Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 L’Oréal Puts a New Wrinkle in Skin Care Research - Happi

L’Oréal Puts a New Wrinkle in Skin Care Research

Samumed, LLC is collaborating with L’Oréal to evaluate the potential skin care applications of SM05253, Samumed’s topical compound derived from the company’s proprietary discovery platform.

Under the terms of the collaboration, L’Oréal will conduct formulation and research studies, expected to begin in early 2018, to evaluate the potential of SM05253 in anti-wrinkle skin care applications.

“The prospect of L’Oréal, the world’s leading beauty company, further developing SM05253 for skin care applications, presents us with a compelling opportunity to capitalize on a valuable, non-core asset,” said Erich Horsley, chief business officer of Samumed. “L’Oréal’s expertise in research and development of skin care compounds, combined with its global footprint, makes it an ideal partner to assume the development of SM05253.”

Samumed says its small-molecule drug platform is harnessing the innate restorative power of the Wnt pathway to reverse the course of severe and prevalent diseases.

The company is also involved in psoriasis treatments. Samumed’s clinical pipeline can be viewed online at www.samumed.com/pipeline. 

Add us as a preferred source on Google

Get the latest Happi news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Happi Newsletters